There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Pfenex (PFNX) and VistaGen Therapeutics (VTGN) with bullish sentiments.
Pfenex (PFNX)
In a report issued on October 7, Andy Hsieh from William Blair reiterated a Buy rating on Pfenex. The company’s shares closed last Monday at $8.90.
According to TipRanks.com, Hsieh is a 1-star analyst with an average return of -3.0% and a 33.3% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Nektar Therapeutics, and Seattle Genetics.
Pfenex has an analyst consensus of Moderate Buy, with a price target consensus of $19.00, implying an 118.1% upside from current levels. In a report issued on October 7, JMP Securities also maintained a Buy rating on the stock with a $19.00 price target.
See today’s analyst top recommended stocks >>
VistaGen Therapeutics (VTGN)
William Blair analyst Tim Lugo maintained a Buy rating on VistaGen Therapeutics on October 9. The company’s shares closed last Monday at $1.06.
According to TipRanks.com, Lugo is a 3-star analyst with an average return of 3.2% and a 33.8% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Collegium Pharmaceutical, and Aclaris Therapeutics Inc.
Currently, the analyst consensus on VistaGen Therapeutics is a Moderate Buy with an average price target of $2.35, an 113.6% upside from current levels. In a report issued on October 8, Maxim Group also maintained a Buy rating on the stock with a $4.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
